Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction
- PMID: 17392282
- DOI: 10.1074/jbc.M608189200
Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction
Abstract
Patients with advanced cancer exhibit multifaceted defects in their immune capacity, which are likely to contribute to an increased susceptibility to infections and disease progression. We demonstrated earlier that curcumin inhibits tumor growth and prevents immune cell death in tumor-bearing hosts. Here we report that tumor-induced immunodepletion involves apoptosis of thymic CD4+/CD8+ single/double positive cells as well as loss of circulating CD4+/CD8+ T cells. Administration of curcumin to tumor-bearing animals resulted in restoration of progenitor, effecter, and circulating T cells. In fact, tumor burden decreased the expression level of the pro-proliferative protein Bcl-2 while increasing the pro-apoptotic protein Bax in T cells. Curcumin down-regulated the Bax level while augmenting Bcl-2 expression in these cells, thereby protecting the immunocytes from tumor-induced apoptosis. A search for the upstream mechanism revealed down-regulation of the common cytokine receptor gamma chain (gammac) expression in T cells by tumor-secreted prostaglandin E2. As a result, Jak-3 and Stat-5a phosphorylation and to a lesser extent Stat-5b phosphorylation were also decreased in T cells. These entire phenomena could be reverted back by curcumin, indicating that this phytochemical restored the cytokine-dependent Jak-3/Stat-5a signaling pathway in T cells of tumor bearers. Overexpressed Stat-5a/constitutively active Stat-5a1*6 but not Stat-5b could efficiently elevate Bcl-2 levels and protect T cells from tumor-induced death, whereas C-terminal truncated Stat-5a713 overexpression failed to do so, indicating the importance of Stat-5a signaling in T cell survival. Thus, these results raise the possibility of inclusion of curcumin in successful therapeutic regimens against cancer.
Similar articles
-
Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.PLoS One. 2009 Oct 8;4(10):e7382. doi: 10.1371/journal.pone.0007382. PLoS One. 2009. PMID: 19812686 Free PMC article.
-
Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.Immunology. 2010 Jul;130(3):418-26. doi: 10.1111/j.1365-2567.2009.03244.x. Epub 2010 May 4. Immunology. 2010. PMID: 20465565 Free PMC article.
-
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.J Invest Dermatol. 2008 Nov;128(11):2728-2735. doi: 10.1038/jid.2008.138. Epub 2008 May 22. J Invest Dermatol. 2008. PMID: 18496567
-
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.Mol Cell Endocrinol. 2017 Aug 15;451:66-70. doi: 10.1016/j.mce.2017.02.019. Epub 2017 Feb 15. Mol Cell Endocrinol. 2017. PMID: 28214593 Free PMC article. Review.
-
Apoptosis: A Target for Anticancer Therapy.Int J Mol Sci. 2018 Feb 2;19(2):448. doi: 10.3390/ijms19020448. Int J Mol Sci. 2018. PMID: 29393886 Free PMC article. Review.
Cited by
-
Tumor-associated macrophages: an effective player of the tumor microenvironment.Front Immunol. 2023 Nov 16;14:1295257. doi: 10.3389/fimmu.2023.1295257. eCollection 2023. Front Immunol. 2023. PMID: 38035101 Free PMC article. Review.
-
Curcumin: potential for hepatic fibrosis therapy?Br J Pharmacol. 2008 Feb;153(3):403-5. doi: 10.1038/sj.bjp.0707580. Epub 2007 Nov 26. Br J Pharmacol. 2008. PMID: 18037917 Free PMC article.
-
An Overview of the Enhanced Effects of Curcumin and Chemotherapeutic Agents in Combined Cancer Treatments.Int J Mol Sci. 2023 Aug 9;24(16):12587. doi: 10.3390/ijms241612587. Int J Mol Sci. 2023. PMID: 37628772 Free PMC article. Review.
-
Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects.Eur J Nutr. 2018 Apr;57(3):929-938. doi: 10.1007/s00394-016-1376-9. Epub 2017 Feb 16. Eur J Nutr. 2018. PMID: 28204880 Free PMC article. Clinical Trial.
-
Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer.Onco Targets Ther. 2017 May 22;10:2675-2683. doi: 10.2147/OTT.S130653. eCollection 2017. Onco Targets Ther. 2017. PMID: 28579805 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous